influenza a

CBS1117 is a virus entry inhibitor with an IC50 of 70 nM for influenza A virus, A/Puerto Rico/8/34 (H1N1). It interferes with the hemagglutinin (HA)-mediated fusion process.

PP7 is a potent inhibitor of PB1-PB2 interaction(IC50 of 8.6 μM).

N-Glycolylneuraminic acid (GcNeu) is a nonhuman sialic acid molecule synthesized in pigs. N-Glycolylneuraminic acid is a receptor of human and animal IAVs.

Zanamivir (GG167) is a guanido-neuraminic acid that is used to inhibit NEURAMINIDASE.

3,4'-Dihydroxyflavone (3,4'-DHF) is an orally active flavonoid that exhibits antiviral activity against the Influenza A virus.

Santin (5,7-Dihydroxy-3,6,4'-trimethoxyflavone) is a flavonoid extracted from birch buds exerting antiproliferative, anti-influenza activity and anti-cancer activity. Santin can be used in studies about anti-IAV drugs.

Influenza A virus-IN-15 (Compound 9b), a quinoline derivative, is a broad-spectrum anti-influenza inhibitor with an IC50 range of 0.88-6.33 μM and demonstrates acceptable cytotoxicity. It inhibits the transcription and replication of viral RNA, making it suitable for research on Influenza A virus (IAV).

Influenza A virus-IN-16 (compound 10) is an effective antiviral agent. It inhibits H7N1 pseudovirus with an EC50 of 0.09 μM.

Influenza A virus-IN-14 (Compound 37) is an inhibitor of the influenza A virus (IAV), effectively suppressing H1N1 with an EC50 of 23 nM. It demonstrates low cytotoxicity, with a CC50 exceeding 100 μM, and reduces cytopathic effects while enhancing the survival rate of Calu3 cells. The compound exhibits synergistic effects with the neuraminidase inhibitor Oseltamivir. However, it shows poor pharmacokinetic properties in CD-1 mice.

Anti-Influenza agent 10 (Compound 41) is an inhibitor of the RNA-dependent RNA polymerase (RdRp) of the influenza A virus. It shows potent antiviral activity against the A/PR/8/34(H1N1) strain, with an IC50 of 0.29 μM and a KD of 4.11 μM. The compound functions by disrupting the interaction between the PA and PB1 subunits, inhibiting the assembly of the viral RdRp complex, and thereby blocking transcription and replication of the viral genome. Anti-Influenza agent 10 also demonstrates significant broad-spectrum efficacy against various influenza strains, such as H3N2, H3N8, and H9N2, with IC50 values of 3.96, 1.91, and 1.45 μM, respectively. It is useful for research on influenza A virus infections.

Influenza A virus-IN-17 (Compound 6a) is a potent inhibitor of the influenza A virus, exhibiting EC90 values of 3.5 μM and 2.6 μM against H3N2 and H1N1 strains, respectively. It also inhibits U2-PB2 chimeric mRNA with an EC90 for cap-snatching polymerase of 2.1 μM.

Influenza A virus-IN-18 (Compound C2e) is an orally active inhibitor targeting the Influenza A virus, displaying an IC50 of 2.5 μM against PR8/H1N1 and 6.42 μM against H3N2. This compound demonstrates high-affinity binding directly to the H1N1/PR8 HA protein with a KD of 0.25 μM. Influenza A virus-IN-18 is applicable for research on Influenza A virus infections.

Influenza hemagglutinin is a type of hemagglutinin found on the surface of the influenza viruses. It is an antigenic glycoprotein. It is responsible for binding the virus to the cell that is being infected. Influenza hemagglutinin proteins bind to cells w

Influenza A virus fragment has the RNA sequence of Leu-Lys-Phe-Ala-Phe-Ser-Met-Met.

Influenza A virus-IN-1, a dihydropyrrolidones derivative, is a highly effective inhibitor of various subtypes of influenza A virus (IAV) with IC 50 values ranging from 3.11 μM to 7.13 μM. It effectively suppresses IAV replication and enhances the expression of key antiviral cytokines, such as IFN-β, and the antiviral protein MxA.

Anti-Influenza agent 3 (compound 11h) is a potent anti-influenza agent with low cytotoxicity for MDCK epithelial cells, inhibiting the M2 WT and S31N ion channel conductivity. It has an EC50 value of 3.29 μM for A/HK/68 (H3N2, M2-WT) and 2.45 μM for A/WSN/33 (H1N1, M2-S31N) strain [1].

Influenza A virus-IN-4 (compound 23b), a derivative of Oseltamivir, is a highly effective neuraminidase inhibitor that exerts potent inhibitory effects on influenza viruses [1].

Influenza A virus-IN-5 (Compound 16e) is a highly potent and orally active agent against influenza A virus (IAV), with an IC50 of 1.29 μM. It effectively inhibits viral RNA transcription and replication while maintaining acceptable levels of cytotoxicity [1].

Influenza A virus-IN-6 (compound 16j) is a potent and selective inhibitor of influenza A virus (IC 50= 3.88 μM, CC50= 36.64 μM), exhibiting anti-IAV activity with low cytotoxicity.

Influenza A virus-IN-7 (compound 16r) is a potent, orally active inhibitor of influenza A virus with an IC50 of 3.43 μM and a CC50 greater than 100 μM. This anti-IAV agent exhibits low cytotoxicity and effectively inhibits viral RNA transcription and replication.

Influenza A virus-IN-8 (S5), a macrocyclic peptide, exhibits no cytotoxicity and acts as a potent inhibitor of Influenza A Virus (IAV), demonstrating significant protease stability, with IC50 values of 6.7 nM for H1 and 6.6 nM for H5 variants. It has a high affinity for H1 variants, binding to a conserved region in the HA stem with a dissociation constant (Kd) of 1.0 nM [1].

Anti-Influenza agent 5 (Compound IIB-2), a chalcone-like derivative, serves as an influenza nuclear export inhibitor, effectively inhibiting oseltamivir-resistant strains and hindering viral proliferation by obstructing the export of influenza virus nucleoprotein [1].

Anti-Influenza A virus NP Antibody (H16-L10-4R5 (HB-65)) is a mouse-derived IgG2a kappa antibody designed to target the nucleoprotein of the influenza A virus. The recommended isotype control for this antibody is Mouse IgG2a kappa, Isotype Control.

Anti-Influenza A H10 Hemagglutinin/HA Antibody (8B805) is a Mouse IgG1 monoclonal antibody targeting Influenza Influenza A H10 Hemagglutinin/HA.